|
1. 行政院衛生署: 民國九十四年死因統計結果. http://www.doh.gov.tw/cht2006/index_populace.aspx. 2. Pejic RN, Lee DT: Hypertriglyceridemia. J Am Board Fam Med 2006, 19:310-316. 3. Kagan A, Harris BR, Winkelstein W, Jr., Johnson KG, Kato H, Syme SL, Rhoads GG, Gay ML, Nichaman MZ, Hamilton HB, et al.: Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: demographic, physical, dietary and biochemical characteristics. J Chronic Dis 1974, 27:345-364. 4. Gordon T, Kannel WB, Castelli WP, Dawber TR: Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch Intern Med 1981, 141:1128-1131. 5. Anderson KM, Castelli WP, Levy D: Cholesterol and mortality. 30 years of follow-up from the Framingham study. Jama 1987, 257:2176-2180. 6. Castelli WP, Anderson K: A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. Am J Med 1986, 80:23-32. 7. Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3:213-219. 8. Austin MA, Hokanson JE, Edwards KL: Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998, 81:7B-12B. 9. Fung MA, Frohlich JJ: Common problems in the management of hypertriglyceridemia. Cmaj 2002, 167:1261-1266. 10. Gouni-Berthold I, Krone W: Hypertriglyceridemia-why, when and how should it be treated? Z Kardiol 2005, 94:731-739. 11. Guerra R, Wang J, Grundy SM, Cohen JC: A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol. Proc Natl Acad Sci U S A 1997, 94:4532-4537. 12. van''t Hooft FM, Lundahl B, Ragogna F, Karpe F, Olivecrona G, Hamsten A: Functional characterization of 4 polymorphisms in promoter region of hepatic lipase gene. Arterioscler Thromb Vasc Biol 2000, 20:1335-1339. 13. Deeb SS, Peng R: The C-514T polymorphism in the human hepatic lipase gene promoter diminishes its activity. J Lipid Res 2000, 41:155-158. 14. Xin X, Srinivasan SR, Chen W, Boerwinkle E, Berenson GS: Interaction effect of Serine447Stop variant of the lipoprotein lipase gene and C-514T variant of the hepatic lipase gene on serum triglyceride levels in young adults: the Bogalusa Heart Study. Metabolism 2003, 52:1337-1342. 15. Lam CW, Yuen YP, Cheng WF, Chan YW, Tong SF: Missense mutation Leu72Pro located on the carboxyl terminal amphipathic helix of apolipoprotein C-II causes familial chylomicronemia syndrome. Clin Chim Acta 2006, 364:256-259. 16. Shachter NS: Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 2001, 12:297-304. 17. Hallman DM, Srinivasan SR, Chen W, Boerwinkle E, Berenson GS: Longitudinal analysis of haplotypes and polymorphisms of the APOA5 and APOC3 genes associated with variation in serum triglyceride levels: the Bogalusa Heart Study. Metabolism 2006, 55:1574-1581. 18. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM: An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001, 294:169-173. 19. Zhao SP, Hu S, Li J, Hu M, Liu Q, Wu LJ, Zhang T: Association of human serum apolipoprotein A5 with lipid profiles affected by gender. Clin Chim Acta 2007, 376:68-71. 20. Lai CQ, Tai ES, Tan CE, Cutter J, Chew SK, Zhu YP, Adiconis X, Ordovas JM: The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore. J Lipid Res 2003, 44:2365-2373. 21. Kao JT, Wen HC, Chien KL, Hsu HC, Lin SW: A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum Mol Genet 2003, 12:2533-2539. 22. Dallongeville J, Lussier-Cacan S, Davignon J: Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J Lipid Res 1992, 33:447-454. 23. Ferre P: The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 2004, 53 Suppl 1:S43-50. 24. Lee CH, Olson P, Evans RM: Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003, 144:2201-2207. 25. Garenc C, Aubert S, Laroche J, Girouard J, Vohl MC, Bergeron J, Rousseau F, Julien P: Population prevalence of APOE, APOC3 and PPAR-alpha mutations associated to hypertriglyceridemia in French Canadians. J Hum Genet 2004, 49:691-700. 26. Williams RR, Hunt SC, Hopkins PN, Wu LL, Lalouel JM: Evidence for single gene contributions to hypertension and lipid disturbances: definition, genetics, and clinical significance. Clin Genet 1994, 46:80-87. 27. Sprecher DL, Harris BV, Stein EA, Bellet PS, Keilson LM, Simbartl LA: Higher triglycerides, lower high-density lipoprotein cholesterol, and higher systolic blood pressure in lipoprotein lipase-deficient heterozygotes. A preliminary report. Circulation 1996, 94:3239-3245. 28. Hopkins PN, Heiss G, Ellison RC, Province MA, Pankow JS, Eckfeldt JH, Hunt SC: Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation 2003, 108:519-523. 29. Shieh SM, Shen M, Fuh MM, Chen YD, Reaven GM: Plasma lipid and lipoprotein concentrations in Chinese males with coronary artery disease, with and without hypertension. Atherosclerosis 1987, 67:49-55. 30. Mead JR, Irvine SA, Ramji DP: Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med 2002, 80:753-769. 31. Braun JE, Severson DL: Regulation of the synthesis, processing and translocation of lipoprotein lipase. Biochem J 1992, 287 ( Pt 2):337-347. 32. Beisiegel U, Weber W, Bengtsson-Olivecrona G: Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc Natl Acad Sci U S A 1991, 88:8342-8346. 33. Iverius PH, Ostlund-Lindqvist AM: Lipoprotein lipase from bovine milk. Isolation procedure, chemical characterization, and molecular weight analysis. J Biol Chem 1976, 251:7791-7795. 34. Vannier C, Ailhaud G: Biosynthesis of lipoprotein lipase in cultured mouse adipocytes. II. Processing, subunit assembly, and intracellular transport. J Biol Chem 1989, 264:13206-13216. 35. Ben-Zeev O, Doolittle MH, Davis RC, Elovson J, Schotz MC: Maturation of lipoprotein lipase. Expression of full catalytic activity requires glucose trimming but not translocation to the cis-Golgi compartment. J Biol Chem 1992, 267:6219-6227. 36. Sparkes RS, Zollman S, Klisak I, Kirchgessner TG, Komaromy MC, Mohandas T, Schotz MC, Lusis AJ: Human genes involved in lipolysis of plasma lipoproteins: mapping of loci for lipoprotein lipase to 8p22 and hepatic lipase to 15q21. Genomics 1987, 1:138-144. 37. Wion KL, Kirchgessner TG, Lusis AJ, Schotz MC, Lawn RM: Human lipoprotein lipase complementary DNA sequence. Science 1987, 235:1638-1641. 38. Enerback S, Gimble JM: Lipoprotein lipase gene expression: physiological regulators at the transcriptional and post-transcriptional level. Biochim Biophys Acta 1993, 1169:107-125. 39. Doolittle MH, Ben-Zeev O, Elovson J, Martin D, Kirchgessner TG: The response of lipoprotein lipase to feeding and fasting. Evidence for posttranslational regulation. J Biol Chem 1990, 265:4570-4577. 40. Ong JM, Kirchgessner TG, Schotz MC, Kern PA: Insulin increases the synthetic rate and messenger RNA level of lipoprotein lipase in isolated rat adipocytes. J Biol Chem 1988, 263:12933-12938. 41. Fried SK, Russell CD, Grauso NL, Brolin RE: Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissues of obese women and men. J Clin Invest 1993, 92:2191-2198. 42. Semenkovich CF, Wims M, Noe L, Etienne J, Chan L: Insulin regulation of lipoprotein lipase activity in 3T3-L1 adipocytes is mediated at posttranscriptional and posttranslational levels. J Biol Chem 1989, 264:9030-9038. 43. Sartippour MR, Lambert A, Laframboise M, St-Jacques P, Renier G: Stimulatory effect of glucose on macrophage lipoprotein lipase expression and production. Diabetes 1998, 47:431-438. 44. Clee SM, Loubser O, Collins J, Kastelein JJ, Hayden MR: The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease. Clin Genet 2001, 60:293-300. 45. Michaud SE, Renier G: Direct regulatory effect of fatty acids on macrophage lipoprotein lipase: potential role of PPARs. Diabetes 2001, 50:660-666. 46. Amri EZ, Teboul L, Vannier C, Grimaldi PA, Ailhaud G: Fatty acids regulate the expression of lipoprotein lipase gene and activity in preadipose and adipose cells. Biochem J 1996, 314 ( Pt 2):541-546. 47. Hunt SC, Province MA, Atwood LD, Sholinsky P, Lalouel JM, Rao DC, Williams RR, Leppert MF: No linkage of the lipoprotein lipase locus to hypertension in Caucasians. J Hypertens 1999, 17:39-43. 48. Wu SY, Fann CS, Jou YS, Chen JW, Pan WH: Association between markers in chromosomal region 17q23 and young onset hypertension: a TDT study. J Med Genet 2002, 39:42-44. 49. Pan WH, Chen JW, Fann C, Jou YS, Wu SY: Linkage analysis with candidate genes: the Taiwan young-onset hypertension genetic study. Hum Genet 2000, 107:210-215. 50. 陳珮: 台灣年輕型高血壓遺傳研究:脂蛋白脂解酶基因與高血壓相關徵狀之關係. 國防醫學院生命科學研究所博士論文 2005. 51. Langlois S, Deeb S, Brunzell JD, Kastelein JJ, Hayden MR: A major insertion accounts for a significant proportion of mutations underlying human lipoprotein lipase deficiency. Proc Natl Acad Sci U S A 1989, 86:948-952. 52. Evans V, Kastelein JJ: Lipoprotein lipase deficiency--rare or common? Cardiovasc Drugs Ther 2002, 16:283-287. 53. Wittekoek ME, Pimstone SN, Reymer PW, Feuth L, Botma GJ, Defesche JC, Prins M, Hayden MR, Kastelein JJ: A common mutation in the lipoprotein lipase gene (N291S) alters the lipoprotein phenotype and risk for cardiovascular disease in patients with familial hypercholesterolemia. Circulation 1998, 97:729-735. 54. Fisher RM, Humphries SE, Talmud PJ: Common variation in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis. Atherosclerosis 1997, 135:145-159. 55. Wittekoek ME, Moll E, Pimstone SN, Trip MD, Lansberg PJ, Defesche JC, van Doormaal JJ, Hayden MR, Kastelein JJ: A frequent mutation in the lipoprotein lipase gene (D9N) deteriorates the biochemical and clinical phenotype of familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1999, 19:2708-2713. 56. Wung SF, Kulkarni MV, Pullinger CR, Malloy MJ, Kane JP, Aouizerat BE: The lipoprotein lipase gene in combined hyperlipidemia: evidence of a protective allele depletion. Lipids Health Dis 2006, 5:19. 57. Nordestgaard BG, Abildgaard S, Wittrup HH, Steffensen R, Jensen G, Tybjaerg-Hansen A: Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation 1997, 96:1737-1744. 58. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG: Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 1999, 99:2901-2907. 59. van Bockxmeer FM, Liu Q, Mamotte C, Burke V, Taylor R: Lipoprotein lipase D9N, N291S and S447X polymorphisms: their influence on premature coronary heart disease and plasma lipids. Atherosclerosis 2001, 157:123-129. 60. Templeton AR: Cladistic approaches to identifying determinants of variability in multifactorial phenotypes and the evolutionary significance of variation in the human genome. Ciba Found Symp 1996, 197:259-277; discussion 277-283. 61. Jump DB: The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem 2002, 277:8755-8758. 62. Montalto MB, Bensadoun A: Lipoprotein lipase synthesis and secretion: effects of concentration and type of fatty acids in adipocyte cell culture. J Lipid Res 1993, 34:397-407. 63. Duque M, Graupner M, Stutz H, Wicher I, Zechner R, Paltauf F, Hermetter A: New fluorogenic triacylglycerol analogs as substrates for the determination and chiral discrimination of lipase activities. J Lipid Res 1996, 37:868-876. 64. Vannier C, Amri EZ, Etienne J, Negrel R, Ailhaud G: Maturation and secretion of lipoprotein lipase in cultured adipose cells. I. Intracellular activation of the enzyme. J Biol Chem 1985, 260:4424-4431. 65. Edwards K, Chan RY, Sawyer WH: Interactions between fatty acids and lipoprotein lipase: specific binding and complex formation. Biochemistry 1994, 33:13304-13311. 66. Murphy MC, Zampelas A, Puddicombe SM, Furlonger NP, Morgan LM, Williams CM: Pretranslational regulation of the expression of the lipoprotein lipase (EC 3.1.1.34) gene by dietary fatty acids in the rat. Br J Nutr 1993, 70:727-736. 67. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J: PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. Embo J 1996, 15:5336-5348. 68. Ren B, Thelen AP, Peters JM, Gonzalez FJ, Jump DB: Polyunsaturated fatty acid suppression of hepatic fatty acid synthase and S14 gene expression does not require peroxisome proliferator-activated receptor alpha. J Biol Chem 1997, 272:26827-26832. 69. Faustinella F, Chang A, Van Biervliet JP, Rosseneu M, Vinaimont N, Smith LC, Chen SH, Chan L: Catalytic triad residue mutation (Asp156----Gly) causing familial lipoprotein lipase deficiency. Co-inheritance with a nonsense mutation (Ser447----Ter) in a Turkish family. J Biol Chem 1991, 266:14418-14424. 70. Kobayashi J, Nishida T, Ameis D, Stahnke G, Schotz MC, Hashimoto H, Fukamachi I, Shirai K, Saito Y, Yoshida S: A heterozygous mutation (the codon for Ser447----a stop codon) in lipoprotein lipase contributes to a defect in lipid interface recognition in a case with type I hyperlipidemia. Biochem Biophys Res Commun 1992, 182:70-77. 71. Previato L, Guardamagna O, Dugi KA, Ronan R, Talley GD, Santamarina-Fojo S, Brewer HB, Jr.: A novel missense mutation in the C-terminal domain of lipoprotein lipase (Glu410-->Val) leads to enzyme inactivation and familial chylomicronemia. J Lipid Res 1994, 35:1552-1560. 72. Kozaki K, Gotoda T, Kawamura M, Shimano H, Yazaki Y, Ouchi Y, Orimo H, Yamada N: Mutational analysis of human lipoprotein lipase by carboxy-terminal truncation. J Lipid Res 1993, 34:1765-1772. 73. Ross CJ, Liu G, Kuivenhoven JA, Twisk J, Rip J, van Dop W, Excoffon KJ, Lewis SM, Kastelein JJ, Hayden MR: Complete rescue of lipoprotein lipase-deficient mice by somatic gene transfer of the naturally occurring LPLS447X beneficial mutation. Arterioscler Thromb Vasc Biol 2005, 25:2143-2150. 74. Kastelein JJ, Jukema JW, Zwinderman AH, Clee S, van Boven AJ, Jansen H, Rabelink TJ, Peters RJ, Lie KI, Liu G, et al.: Lipoprotein lipase activity is associated with severity of angina pectoris. REGRESS Study Group. Circulation 2000, 102:1629-1633. 75. Beauchamp MC, Renier G: Homocysteine induces protein kinase C activation and stimulates c-Fos and lipoprotein lipase expression in macrophages. Diabetes 2002, 51:1180-1187. 76. Maingrette F, Renier G: Leptin increases lipoprotein lipase secretion by macrophages: involvement of oxidative stress and protein kinase C. Diabetes 2003, 52:2121-2128.
|